Thema
Carboplatin
9
Paclitaxel
9
Olaparib
8
PARP inhibitor
8
Pharmacokinetics
8
Phase I
8
Journal Article
7
Clinical Trial, Phase I
5
Research Support, Non-U.S. Gov't
5
Antineoplastic Agents
3
BG3F62OND5
3
P88XT4IS4D
3
Phthalazines
3
Piperazines
3
WOH1JD9AR8
3
olaparib
3
EC 2.7.10.1
2
Protein Kinase Inhibitors
2
Sulfonamides
2
1X8F5A3NA0
1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine
1
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
1
Breast Neoplasms - drug therapy
1
Breast Neoplasms - genetics
1
Breast Neoplasms - pathology
1
Capsules
1
Carboplatin - administration & dosage
1
Class I Phosphatidylinositol 3-Kinases
1
DA87705X9K
1
EC 2.7.1.137
1
EC 2.7.11.24
1
EGFR protein, human
1
Epidermal growth factor receptor
1
Epidermal growth factor receptor inhibitor
1
ErbB Receptors
1
Erlotinib
1
Erlotinib Hydrochloride
1
Erlotinib hydrochloride
1
Fallopian Tube Neoplasms - drug therapy
1
Fallopian Tube Neoplasms - genetics
1
Fallopian Tube Neoplasms - pathology
1
Indazoles
1
Letter
1
Mitogen-Activated Protein Kinases
1
Multicenter Study
1
Ovarian Neoplasms - drug therapy
1
Ovarian Neoplasms - genetics
1
Ovarian Neoplasms - pathology
1
Paclitaxel - administration & dosage
1
Phase I clinical trial
1
mehr ...